Investor
ANDERA PARTNERS
CIK 0001757283 · filed 2026-05-11 · SEC filing
13F book
$176.9M
Positions
7
2 new · 0 sold
Largest name
30.4%
Kestra Med Technologies Ltd
Est. mark
−$20.4M
Price effect on 5 names still held. Flow $20.8M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Kestra Med Technologies Ltd | — | 2.7M | $53.7M | 30.4% | −$16.7M | Added−$13.6M |
| Evommune, Inc. | EVMN | 1.9M | $43.6M | 24.7% | $11.1M | Held |
| Mineralys Therapeutics, Inc. | MLYS | 1.59M | $43.1M | 24.4% | −$14.6M | Held |
| Agomab Therapeutics Nv | AGMB | 1.54M | $16.1M | 9.1% | — | New |
| Inventiva Sa | — | 1.82M | $10.1M | 5.7% | $1.64M | Held |
| Abivax Sa | — | 78.1K | $8.7M | 4.9% | −$1.84M | Held |
| Nyxoah S A | — | 522.1K | $1.52M | 0.9% | — | New |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.